Rocket Pharmaceuticals

Update in progress

RCKT (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Rocket Pharmaceuticals, Inc. is a late‑stage biotechnology company developing genetic therapies for rare diseases in the United States. It pursues in vivo AAV programs for Danon disease (RP-A501, Phase 2), PKP2‑ACM (RP-A601, Phase 1), and BAG3‑DCM (preclinical). Ex vivo LV programs cover LAD‑I, FA, and PKD. It licenses from academic and research partners and was founded in 1999, based in Cranbury, New Jersey.

Company score

Sentiment: -0.20; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.33; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.37; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.18; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive